Tiotropium / Respimat One-Year Study

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

Key facts

Study ID

NCT00168831

Run by

Boehringer Ingelheim

People needed

1007

Starts

2003-02-01

Last updated by the study team

2014-05-20

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Boehringer Ingelheim Investigational Site — La Jolla, California, United States
• Boehringer Ingelheim Investigational Site — Long Beach, California, United States
• Boehringer Ingelheim Investigational Site — San Luis Obispo, California, United States
• Boehringer Ingelheim Investigational Site — Gainesville, Florida, United States
• Boehringer Ingelheim Investigational Site — Hallandale, Florida, United States
• Boehringer Ingelheim Investigational Site — Hines, Illinois, United States
• Boehringer Ingelheim Investigational Site — Chesterfield, Missouri, United States
• Boehringer Ingelheim Investigational Site — Bay Shore, New York, United States
• Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• Boehringer Ingelheim Investigational Site — Houston, Texas, United States
• Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
• Boehringer Ingelheim Investigational Site — Garran, Australian Capital Territory, Australia
• Boehringer Ingelheim Investigational Site — Adelaide, South Australia, Australia
• Boehringer Ingelheim Investigational Site — Nedlands, Western Australia, Australia
• Boehringer Ingelheim Investigational Site — Innsbruck, Austria
• Boehringer Ingelheim Investigational Site — Mittersill, Austria
• Boehringer Ingelheim Investigational Site — Schwechat, Austria
• Baumgartner Hohe Otto Wagner Spital Wien — Vienna, Austria
• Boehringer Ingelheim Investigational Site — Vienna, Austria
• Boehringer Ingelheim Investigational Site — Wels, Austria
• Boehringer Ingelheim Investigational Site — Winnipeg, Manitoba, Canada
• Boehringer Ingelheim Investigational Site — Hamilton, Ontario, Canada
• Boehringer Ingelheim Investigational Site — Toronto, Ontario, Canada
• Boehringer Ingelheim Investigational Site — Montreal, Quebec, Canada
• Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.